Picture of Lucid Diagnostics logo

LUCD Lucid Diagnostics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Brief: NCI-Sponsored Study Shows Positive Data For Lucid Diagnostics' Esoguard® Esophageal Dna Test In Patients Without Symptomatic Gerd

April 24 (Reuters) - Lucid Group Inc LCID.O:

NCI-SPONSORED STUDY SHOWS POSITIVE DATA FOR LUCID DIAGNOSTICS' ESOGUARD® ESOPHAGEAL DNA TEST IN PATIENTS WITHOUT SYMPTOMATIC GERD

Source text: ID:nPn7s8bCMa

Further company coverage: LCID.O

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Lucid Diagnostics

See all news